5 ms·
Tumor-derived erythropoietin acts as immunosuppressive switch in cancer immunity
- w10-1 2y agoIt would be nice to see the original article. But at face value this looks very promising. This identifies one way solid tumors avoid immune attack and identifies corresponding therapeutic targets that could span solid tumor types. EPO (erythropoietin) (aside from stimulating red-blood-cell production) also converts tumor-local macrophages from attacking to suppressing immune attacks. Tumors are shown to produce EPO themselves. Tumors spontaneously regressed due to revived immune response when blocking either EPO or the EPO receptor on the macrophages. The model was murine liver cancer, but high blood EPO levels are known to be poor prognosticators in many solid tumor cancers. This summary points to NRF2 (nuclear factor erythroid 2-related factor 2) as a regulatory target, but without any detail. AFAICT there are no approved drugs blocking EPO receptors and no drugs to reduce EPO; there are some anti-anemia drugs that increase production.
- badmonster 2y agoyeah i cannot read the full article
- jjtheblunt 2y ago> AFAICT there are no approved drugs blocking EPO receptors and no drugs to reduce EPO Such receptors have a protein structure definitive for them, so a bespoke RNA (mRNA) therapy might be a means of generating receptor blockers? Edit: looks like this applicable. two interesting articles... https://pubmed.ncbi.nlm.nih.gov/28629523/ https://pubmed.ncbi.nlm.nih.gov/28629523/ https://www.genengnews.com/topics/cancer/blocking-erythropoietin-signaling-in-mice-converts-liver-tumors-into-immunotherapy-responders/ https://www.genengnews.com/topics/cancer/blocking-erythropoi...
- mariusor 2y agoLet me guess, this research was sponsored by Lance Armstrong?
- hinkley 2y agoHuh. I assumed this was going to be a collision of acronyms but erythropoietin is the same EPO used medicinally to treat anemia and abused by several generations of endurance athletes (complications include strokes and heart attacks from blood clot). It’s a stress-signaling hormone produced by the kidneys when they detect hypoxia and triggers more red blood cell production in bone marrow.
- mariusor 2y agoWhat makes this mildly funny, though I admit in quite poor taste, is the fact that Armstrong did indeed suffer of cancer to which he lost a testicle before his comeback to win multiple Tour de France back to back. So theoretically his EPO positive results could be attributed to those tumors producing it, if this research is to be believed. Maybe not all of the times though.
- hinkley 2y agoHe was on steroids post treatment as well. Chemotherapy likes to cause anemia. In fact I think that’s where I first heard of EPO. Some survivor crowing about the efficacy at making them feel human again. And they’ve discovered in more recent studies that steroid use has effects that last about twice as long as it’s detectable in your body (2 vs 1 year?). If sports weren’t such a young person’s game, I’d worry about people taking off for “surgery” and coming back built like a linebacker but testing clean.
- nonameiguess 2y agoLance Armstrong never failed a drug test. The CEO of the insurance company responsible for underwriting bonus payments for Tour de France wins had read a book full of circumstantial evidence of the US Postal Service team doping and contested paying out the bonus. He knew they'd lose, but wanted to force the hands of some investigative body with real power to actually look into it. Federal prosecutors took up the case for a couple years, but then dropped it. Then USADA finally got a bunch of his former teammates and medical staffers to testify against him. Lance didn't even contest the finding because the evidence was so overwhelming, he figured his best course of action at that point was trying to keep the report confidential and winning in the court of public opinion instead, convincing all of his adoring fans that he was the victim of a witch hunt. Obviously, that didn't work, but I guess he was just ahead of his time. These days, he could have run for president.
- hinkley 2y agoTumors excreting chemicals to prevent destruction doesn’t sound like DNA damage, that sounds like evolution. We know some cancers can be caused by viruses. And we know a few cancers that act like viruses in dogs and Tasmanian devils, and some rare cases in humans. We only figured out that ulcers are bacterial in origin within the lifetimes of many HN readers, and there are signs that other GI issues may be bacterial or viral (or bacteria-targeting viral) as well. Maybe we need to start culturing and DNA testing cancers.
- Kalanos 2y agoYou're right, DNA damage is just one of the types of genetic variation in cancer. There are many other structural variations that act like remixes. "Maybe we need to start culturing and DNA testing cancers." I assure you this is being done at a massive scale. Due to cellular stress, cancer cells disobey multi-cellular governance. They behave more like independent organisms fighting for survival, reverting to primal programming.
- hinkley 2y agoOh I know we are trying to genomically test them for oncology research and potential treatment plans, but do they do paternity tests on them? I was trying to remember which mammal in Australia gets tumors from fighting, and I found a reference to a mother getting melanoma from her daughter. It’s unclear to me whether the cancer transmission was rare or the identification is rare.
- rflrob 2y agoThere’s very often a comparison to the somatic (i.e. non-cancer) genome of the same patient. It’s a great way to quality control that there wasn’t some sample mixup in the lab. Transmission of cancer is rare in humans—if it were not, it would make someone’s career to find many cases of it. While we can’t say that all sheep are white, we’ve looked at enough of them to say that black sheep are not common. Furthermore, it’s very clear how the Tasmanian devil cancer is spread—it’s around the mouth while they are biting each others faces; it’s not as obvious how one would spread most human cancers.
- SimplyUnknown 2y agoFull paper link for the interested: https://ehdijrb3629whdb.tiiny.site https://ehdijrb3629whdb.tiiny.site
- damnitbuilds 2y ago"404 Sorry, this content doesn't exist."
- biotechbio 2y agoThis is a pretty cool study with some interesting findings! Cancer immunotherapy has a long history but has become very prominent in recent years. (Fun fact: the senior author on this paper, Ed Engleman, co-founded of one of the first cancer cell therapy companies, Dendreon, in the early 90s). However, the success of immunotherapies has been limited by the immune-exclusionary nature of the tumor microenvironment (TME). Why some tumors are immune-hot and others are immune-cold is still a very open research question. In this study, the authors demonstrate pretty convincingly that erythropoietin (EPO, a hormone that stimulates red blood cell production in the bone marrow) reduces the recruitment of tumor-cell-killing T cells to the TME. It does this by acting on tumor macrophages, another type of immune cell, and changes the state of these cells to facilitate accumulation of immunosuppressive cells. They work out the mechanism largely through mouse models and associative analysis in human tissue samples, but I thought it was interesting that this finding aligns with the clinical observation that cancer patients who receive recombinant EPO for treatment of anemia frequently experience tumor progression. After reading this, I am going back to check out EPO expression in old datasets that I worked with haha.
- ramraj07 2y agoI actually don't mind if it's true, but your comment was the first time I got a tingle that this was AI generated but I still could tell it likely wasn't. Maybe used it to rewrite parts of your comment? Anyways i appreciate it and agree with you. I myself am gonna go check in the cancer cell line encyclopedia, which IME is the single cleanest large dataset curated in biology in decades. For others who might be curious, this study is genuinely good (evidenced somewhat by it being published in Science, as a study that is not in humans but still showing actual cancer curing efficacy not just some pathway finding) is that they use difficult but necessary model systems that emulate real tumor environments - these are spontaneous tumors that show up in mice that have full immune systems. Literally 99.9% of cancer study papers don't use such systems and in my opin9on get fully invalidated for most interpretation. Anyways I'm curious if the microenvironment will just evolve quickly to be EPO independent, as it typically seems to do something like that in real long term tumor environments you encounter in people compared to mouse models.